The Impact of Connective Tissue Diseases on the Inpatient Outcomes of Congestive Heart Failure Patients

Anantha Sriharsha Madgula 1, Daniel Condit 1, Jinjian Mu 2, Kai Chen 3

1. Internal Medicine, University of Connecticut School of Medicine, Farmington, USA 2. Statistics, University of Connecticut, Storrs, USA 3. Cardiology, University of Connecticut Health Center, Farmington, USA

Corresponding author: Anantha Sriharsha Madgula, madgula.anantha@gmail.com

Abstract

Background

Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are autoimmune diseases with chronically elevated inflammatory activity. Treatments typically have been aimed at decreasing inflammation. While RA and SLE are known to have a high incidence of congestive heart failure (HF), the mechanism behind this remains elusive. We sought to assess the outcomes of HF patients with either RA or SLE as opposed to HF patients without RA or SLE.

Methods

We conducted a retrospective analysis of the Healthcare Utilization Project - National Inpatient Sample Database from 2010 to 2015 (third quarter). Patients with a primary admitting diagnosis of HF were queried, and those with or without a diagnosis of either SLE or RA were separated into two groups. In-hospital mortality, total charges (TOTCHG), and length of stay (LOS) were analyzed with a multivariate regression model adjusted for demographical and comorbidity variables, using generalized linear models with family binomial, gamma, and negative-binomial, respectively. A p-value smaller than 0.05 was deemed statistically significant. All the statistical analyses were performed in R 3.5.5 (R Core Team, 2013, http://www.R-project.org/).

Results

The in-hospital mortality (3.4% v/s 4.43%), mean TOTCHG ($46k v/s $51k), and mean LOS (5.79 v/s 6.12 days) were significantly lower in HF patients with RA/SLE when compared with HF patients without RA/SLE. A younger age (70.5 v/s 72.6 years) and a female preponderance (75% v/s 51%) were evident in the RA/SLE group. Both groups consistently showed a significant disparity in the rates of hospitalization, which was inversely related to household income. p-value was less than 0.001 for all the above outcomes.

Conclusions

RA/SLE patients are associated with better in-hospital outcomes of HF. The underlying mechanism is unclear in terms of this paradox. Given the fact that the majority of RA/SLE patients are treated with agents aimed at decreasing inflammation, this may shed light on the role of inflammation being an important contributor to HF and implicate a future therapeutic direction.

Introduction

Connective tissue diseases (CTD), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), polymyositis, and dermatomyositis, are autoimmune inflammatory disorders that can lead to multiorgan involvement. While musculoskeletal and dermatologic manifestations are traditionally at the forefront, all these disorders can lead to a range of cardiac conditions, including coronary artery disease, conduction abnormalities, valvular disorders, and myocardial and pericardial disease. A cardiac manifestation of interest is congestive heart failure (HF). Patients with CTDs have been shown to be at a higher risk of this significant cardiac comorbidity, including HF in multiple studies [1-3]. Despite the increased prevalence of HF in these patients, there is a paucity of data on the outcomes of patients with CTDs when they are hospitalized for HF.

Materials And Methods

Data source
Data were queried using the National Inpatient Sample developed in part by the Healthcare Cost and Utilization Project. It is an extensive publicly available all-payer database in the United States that represents a sample of hospitalization administrative data with approximately 35-million hospital admissions per year. Each unit of analysis is one hospital discharge, and hence readmissions are not identifiable. The database covers about 95% of the United States population and about 94% of all community hospital discharges [4].

We queried adults over the age of 18 years using the Clinical Classification Software (CCS) for the International Classification of Diseases (ICD), 9th revision, clinical modification codes that were developed as part of this database. It is a diagnosis and procedure categorization scheme that clusters multiple ICD codes into a smaller number of clinically meaningful categories.

**Study population**

We queried the database from January 1, 2010, to September 30, 2015, for individuals carrying a diagnosis of congestive heart failure using the CCS code 108 (Table 1). We then split this population between those carrying a diagnosis code of RA and related disorders, SLE and CTD (CCS codes 202 or 210, respectively), and those without either condition (Table 1).
| CCS Code 108 | ICD-9  | Dx                      | ICD-9  | Dx                      |
|--------------|--------|-------------------------|--------|-------------------------|
| 39891        | Rheumatic congestive heart failure | 42831  | Acute diastolic heart failure |
| 4280         | Heart failure                          | 42832  | Chronic diastolic heart failure |
| 4281         | Left heart failure                      | 42833  | Acute on chronic diastolic heart failure |
| 42820        | Systolic heart failure                  | 42840  | Combined systolic and diastolic heart failure |
| 42821        | Acute systolic heart failure            | 42841  | Acute combined systolic and diastolic heart failure |
| 42822        | Chronic systolic heart failure          | 42842  | Chronic combined systolic and diastolic heart failure |
| 42823        | Acute on chronic systolic heart failure | 42843  | Acute on chronic combined systolic and diastolic heart failure |
| 42830        | Diastolic heart failure                 | 4289   | Heart failure, unspecified |

| CCS Code 202 | ICD-9  | Dx                      | ICD-9  | Dx                      |
|--------------|--------|-------------------------|--------|-------------------------|
| 7140         | Rheumatoid arthritis                   | 71433  | Monoarticular juvenile rheumatoid arthritis |
| 7141         | Felty’s syndrome                        | 7144   | Chronic post-rheumatic arthropathy |
| 7142         | Other rheumatoid arthritis with visceral or systemic involvement | 71481  | Rheumatoid lung |
| 71430        | Polymyositis                            | 71489  | Other specified inflammatory polyarthropathies |
| 71431        | Polymyositis                            | 7149   | Unspecified inflammatory polyarthropathy |
| 71432        | Polymyositis                            | 7200   | Ankylosing spondylitis |

| CCS Code 210 | ICD-9  | Dx                      | ICD-9  | Dx                      |
|--------------|--------|-------------------------|--------|-------------------------|
| 7100         | Systemic lupus erythematosus            | 7104   | Polymyositis             |
| 7101         | Systemic sclerosis                      | 7108   | Other specified diffuse diseases of connective tissue |
| 7102         | Sicca syndrome                          | 7109   | Unspecified diffuse diseases of connective tissue |
| 7103         | Dermatomyositis                          |        |                         |

**TABLE 1: International Classification of Diseases-9 Code accompanying Clinical Classification Software Code 108 (congestive heart failure), 202 (rheumatoid arthritis and related disorders), 210 (systemic lupus erythematosus and connective tissue disorders)**

CCS = Clinical Classification Software; Dx = Diagnosis; ICD = for International Classification of Diseases

**Variables**

Primary outcomes of interest were in-hospital outcomes, including the length of stay, inpatient mortality, and total charges (Table 3). For cost analysis, the National Inpatient Sample database provides total charges that reflect the amount billed by the hospital for services rather than the actual costs of the amount received as reimbursement. Demographics including age, gender, median household income, and race were also compared for descriptive analysis. Comorbidities were established using the Elixhauser-determined comorbidities (Table 3).
| Outcomes | HF (n=6,433,756) | HF with CTDs (n=170,721) | HF without CTDs (n=6,263,035) | p-value |
|----------|------------------|-------------------------|-----------------------------|--------|
| Mortality | 283,499 (4%)     | 5,884 (3.4%)            | 277,615 (4.4%)              | <0.001 |
| Total Charges ($) | 51,731       | 46,256                   | 51,880                      | <0.001 |
| Length of stay (days) | 6.11         | 5.79                     | 6.12                        | <0.001 |

TABLE 2: Comparison of primary outcomes
CTDs = Connective tissue disorders; HF = Congestive heart failure

Values are reported as mean with n (%) unless mentioned otherwise. Mortality, total charges, and length of stay were regressed on the group variable, which was then adjusted for demographical and comorbidity variables using generalized linear models with family binomial, gamma, and negative-binomial, respectively. A p-value smaller than 0.05 was deemed to be statistically significant.
|                           | HF          | HF with CTDs | HF without CTDs | p-value |
|--------------------------|-------------|--------------|-----------------|---------|
| **Mean Age (years)**     | 72.7        | 70.54        | 72.76           | <0.001  |
| **Female Gender**        | 3,322,774 (52%) | 128,168 (75.0%) | 3,194,606 (51.0%) | <0.001  |
| **Income also(quartile)**|             |              |                 | <0.001  |
| First quartile           | 2,028,499 (32%) | 53,191 (32%)  | 1,975,308 (32%) |         |
| Second quartile          | 1,662,709 (26%) | 43,494 (26%)  | 1,619,215 (26%) |         |
| Third quartile           | 1,459,119 (23%) | 38,995 (23%)  | 1,420,124 (23%) |         |
| Fourth quartile          | 1,153,846 (18%) | 32,004 (19%)  | 1,121,842 (18%) |         |
| **Race**                 |             |              |                 | <0.001  |
| White                    | 4,260,861 (71%) | 110,379 (69%) | 4,150,482 (71%) |         |
| Black                    | 1,040,478 (17%) | 31,975 (20%)  | 1,008,503 (17%) |         |
| Hispanic                 | 405,618 (7%)  | 10,325 (6%)  | 395,293 (7%)    |         |
| Asian or Pacific Islander| 102,270 (2%) | 2,074 (1%) | 100,196 (2%) |         |
| Native American          | 32,365 (1%)  | 1,006 (1%)  | 31,359 (1%)     |         |
| Other                    | 142,816 (2%) | 3,408 (2%) | 139,408 (2%) |         |
| **Comorbidities**        |             |              |                 |         |
| AIDS                     | 11,331 (0%) | 122 (0%) | 11,209 (0%) | <0.05  |
| Alcohol Abuse            | 190,329 (3%) | 2,315 (1%) | 188,014 (3%) | <0.05  |
| Deficiency Anemia        | 1904,272 (30%) | 58,270 (34%) | 1,846,002 (29%) | <0.05  |
| Chronic Blood Loss Anemia| 88,760 (1%) | 2,350 (1%) | 86,410 (1%) | 0.92   |
| Diabetes Mellitus Uncomplicated | 2,069,454 (32%) | 44,051 (26%) | 2,025,403 (32%) | <0.05  |
| Diabetes Mellitus Complicated | 686,542 (11%) | 11,784 (7%) | 674,758 (11%) | <0.05  |
| Hypertension             | 4,512,944 (70%) | 117,664 (69%) | 4,395,280 (70%) | <0.05  |
| Hypothyroidism           | 1,105,917 (17%) | 37,067 (22%) | 1,068,850 (17%) | <0.05  |
| Obesity                  | 1,117138 (17%) | 25,906 (15%) | 1,091,232 (17%) | <0.05  |
| Peripheral Vascular Disease | 835,467 (13%) | 18,269 (11%) | 817,198 (13%) | <0.05  |
| Pulmonary Circulation Disorders | 425,542 (7%) | 14,893 (9%) | 410,649 (7%) | <0.05  |
| Renal Failure            | 2,274,911 (35%) | 52,224 (31%) | 2,222,687 (35%) | <0.05  |

**TABLE 3: The basic characteristics and comorbidities of the study population**

AIDS = Acquired immunodeficiency syndrome; CTDs = Connective tissue disorders; HF = Congestive heart failure

Results are represented as n (%) unless mentioned otherwise. Between-group differences were tested using the chi-square test and the Wilcoxon rank-sum test.

---

**Statistical analysis**
All variables were summarized together and separately by group, mean ± standard deviation for numerical variables, and frequency and proportion for categorical variables. The Wilcox rank-sum test or chi-square test was applied to test between-group differences. Mortality, total charges, and length of stay were regressed on the group variable, which was then adjusted for demographical and comorbidity variables using generalized linear models with family binomial, gamma, and negative-binomial, respectively. A p-value smaller than 0.05 was deemed to be statistically significant. All the statistical analyses were performed in R 3.5.5 (R Core Team, 2013, http://www.R-project.org/).

Results

Our study included a total of 6,453,756 individuals with HF. Among these individuals, there was a total of 170,721 individuals with CTDs whom we classified as group 1 and 6,263,035 individuals without CTDs whom we classified as group 2. Primary outcomes, including inpatient mortality, length of stay, and total charges, were adjusted for demographic variables and comorbidity variables. Inpatient mortality in group 1 was lower at 3.45% as opposed to 4.43% among group 2 (p<0.001). The mean length of stay was lower in group 1 at 5.79 days as opposed to 6.12 days in group 2 (p<0.001). The mean charges were lower in group 1 at $46,256 as opposed to $51,880 in group 2 (p<0.001) (Table 2).

A comparison of basic characteristics between the two groups revealed group 1 being younger and female-dominant as shown in Table 2. There was a general trend of increased hospitalization rate with a decrease in household income for the entire cohort.

We further analyzed HF with CTDs population by stratifying patients with either systolic HF or diastolic HF (Table 4). Unfortunately, ICD coding does not differentiate heart failure based on ejection fraction but rather on whether the failure is systolic or diastolic. Diastolic HF is more prevalent and female-dominant than systolic HF in this cohort, consistent with previous findings in patients with RA [1]. Diastolic HF showed lower mortality and less mean total charges than systolic HF, after adjusting for comorbidities, including diabetes mellitus, hypertension, hypothyroidism, obesity, pulmonary circulation disorders, and renal failure. However, the length of stay was longer in patients with diastolic HF.

|                  | Systolic HF with CTDs (n = 41,928) | Diastolic HF with CTDs (n= 66,658) | p-value |
|------------------|----------------------------------|----------------------------------|---------|
| Mortality        | 1,466 (3.50%)                    | 2,047 (3.07%)                    | <0.001  |
| Mean charges in $| 49,097                           | 45,355                           | <0.001  |
| Length of stay in days | 5.84                         | 5.96                             | <0.001  |
| Age (years)      | 69.01                            | 72.45                            | <0.001  |
| Gender in females| 27,808 (66.32%)                  | 54,266 (81.41%)                  | <0.001  |

TABLE 4: Comparison between systolic HF and diastolic HF

HF = Congestive heart failure; CTDs = Connective tissue disorders

Values are reported as mean with n (%) unless mentioned otherwise. Mortality, total charges, and length of stay were regressed on the group variable, which was then adjusted for demographical and comorbidity variables using generalized linear models with family binomial, gamma, and negative-binomial, respectively. A p-value smaller than 0.05 was deemed to be statistically significant.

Discussion

The results of our investigation showed a statistically significant decrease in mortality, length of stay, and total charges for hospitalization in HF with CTDs as compared to HF without CTDs. The difference in length of stay, though statistically significant, we realize, has little relevance clinically given the eight-hour difference. Similarly, a study done by Suero and Hajjali showed that in-hospital mortality for patients with acute myocardial infarction and CTD was lower than the general population [5]. The reason for better outcomes among hospitalized patients with a history of these inflammatory diseases is currently speculative. It is plausible that baseline anti-inflammatory treatment could have played a cardioprotective role. However, this is out of the scope of our study, as the database we used does not provide us with this information. If we had access to the medications our patients were on, it would provide great insight into their role.

Several pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interferon-gamma, interleukin-1-beta, interleukin-6, interleukin-17, and interleukin-18 have been implicated in the pathogenesis of heart failure [6]. The role of TNF-alpha was recognized in 1990, and it has been known to induce cardiomyocyte dysfunction, cardiomyocyte hypertrophy, and fibrosis [6-7]. Anti-TNF-alpha targeted
inhibition for cardiac dysfunction has been proven beneficial in animal models; however, this could not be translated to humans [6]. Furthermore, these medications have been shown to worsen outcomes in patients with advanced heart failure with New York Heart Association classes III-IV [7]. The mainstay of treatment for CTDs, primarily RA and SLE, which have been studied extensively, include immunomodulators like methotrexate, sulfasalazine, and hydroxychloroquine. A study done by Therman et al. showed that methotrexate appeared to be protective against heart failure among patients with RA. It appeared to reduce the risk of developing heart failure among RA patients by half [8]. Another study done by Bernatsky et al. showed a 20% reduction in the risk of hospitalization with HF among RA patients with methotrexate [9]. Together, anti-inflammatory agents may play an important role in the disease process of heart failure.

In the HF with CTDs group, there was a significantly lower prevalence in diabetes, hypertension, renal failure, peripheral vascular disease, obesity, and alcohol abuse. These comorbidities are known to be independent risk factors for HF. Nevertheless, in-hospital outcomes remain statistically different after adjusting for the aforementioned comorbidities.

Analysis of socioeconomic trends revealed a significantly higher rate of hospitalization among patients with a lower household income. This was in agreement with the findings previously seen in multiple studies [10] and again highlighted the socioeconomic disparities in health.

Further examination of systolic HF and diastolic HF subgroups has shown a similar trend in inpatient outcomes, including lower in-hospital mortality and mean charges in the diastolic HF subgroup. Our results are in line with the general trends observed in the entire HF population, despite the much higher female prevalence in this CTDs subpopulation.

Limitations
The national inpatient sample data represents hospitalization episodes and does not contain information about individual patient’s medications or rehospitalization. Moreover, coding inaccuracies and inconsistencies are inevitable. Despite using CCS codes to identify clinical conditions, it is based on ICD codes, and relying on these ICD codes results in the exclusion of about one-third of the patients with clinical evidence of HF. This is further worsened as data is usually analyzed by the first listed diagnosis. Cost estimates used based on this data are amounts billed by the hospital and not insurance reimbursement rates. Despite using Elixhauser comorbidities in our study, these have been developed for use in administrative rather than clinical studies. Further data points differentiating index diagnosis admissions and readmission for HF would have further added strength to the study. A new diagnosis of HF is usually worked up intensively with procedures such as left heart catheterization, for instance, and can add to the overall cost of the admission. Also, due to the limitations of the database, we were unable to differentiate between left heart failure and right heart failure, which would add another dimension to the study.

Conclusions
To our knowledge, this is the first study analyzing HF inpatient outcomes related to underlying CTDs. Overall, the outcomes in HF patients with CTDs were better when compared with HF patients without CTDs. Further research with a prospective design will help validate the findings and provide insight into the mechanisms.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that there is no financial support in any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Suero G, Hajiali R: Abstract 11185: in-hospital mortality in patients with connective tissue disease presenting with acute myocardial infarction. Circulation. 2020, 128:A11185.
2. Arora S, Patel P, Lahaewala S, et al.: Etiologies, trends, and predictors of 30-day readmission in patients with heart failure. Am J Cardiol. 2017, 5:760-769. 10.1016/j.amjcard.2016.11.022
3. Bernatsky S, Hudson M, Siusa S: Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology. 2005, 44:677-680. 10.1093/rheumatology/keh610
4. HCUP National Inpatient Sample (NIS) Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. (2012). https://www.hcup-us.ahrq.gov/news/exhibit_booth/nis_brochure.jsp.
5. Kim CH, Al-Kindi SG, Jandali B, Askari AD, Zacharias M, Oliveira GH: Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2017, 103:227-233.
6. Løgstrup BB, Ellingsen T, Pedersen AB, Kjærgaard A, Bøtker HE, Maeng M: Development of heart failure in patients with rheumatoid arthritis: a Danish population-based study. Eur J Clin Invest. 2018, 48:e12915.
7. Mann DL, McMurray JIV, Packer M, et al.: Targeted anticytokine therapy in patients with chronic heart failure. Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004, 109:1594-1602. 10.1161/01.CIR.0000124490.27666.B2
8. Myasoedova E, Crowson CS, Nicola PJ, et al.: The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011, 38:1601-1606. 10.3899/jrheum.100979
9. Schau T, Gottwald M, Arbach O, et al.: Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol. 2015, 42:2029-2037. 10.3899/jrheum.141647
10. Shirazi LF, Bissett J, Romeo F, Mehta JL: Role of inflammation in heart failure. Curr Atheroscler Rep. 2017, 19:27. 10.1007/s11883-017-0660-3